NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.
The use of positron emission tomography (PET) is increasing rapidly in the United States, with the most common use of PET scanning related to oncology. It is especially useful in the staging and management of lymphoma, lung cancer, and colorectal cancer, according to a panel of expert radiologists, surgeons, radiation oncologists, nuclear medicine physicians, medical oncologists, and general internists convened in November 2006 by the National Comprehensive Cancer Network. The Task Force was charged with reviewing existing data and developing clinical recommendations for the use of PET scans in the evaluation and management of breast cancer, colon cancer, non-small cell lung cancer, and lymphoma. This report summarizes the proceedings of this meeting, including discussions of the background of PET, possible future developments, and the role of PET in oncology.
Podoloff
Donald A
DA
Advani
Ranjana H
RH
Allred
Craig
C
Benson
Al B
AB
Brown
Elizabeth
E
Burstein
Harold J
HJ
Carlson
Robert W
RW
Coleman
R Edward
RE
Czuczman
Myron S
MS
Delbeke
Dominique
D
Edge
Stephen B
SB
Ettinger
David S
DS
Grannis
Frederic W
FW
Hillner
Bruce E
BE
Hoffman
John M
JM
Kiel
Krystyna
K
Komaki
Ritsuko
R
Larson
Steven M
SM
Mankoff
David A
DA
Rosenzweig
Kenneth E
KE
Skibber
John M
JM
Yahalom
Joachim
J
Yu
Jq Michael
JM
Zelenetz
Andrew D
AD
D001943:Breast Neoplasms / Q000175:diagnosis / Q000628:therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis / Q000628:therapy; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000628:therapy; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008223:Lymphoma / Q000175:diagnosis / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D009369:Neoplasms / Q000175:diagnosis*; D049268:Positron-Emission Tomography; D011379:Prognosis; D014057:Tomography, X-Ray Computed
D019788:Fluorodeoxyglucose F18